AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 11 - (NewsRx.com & NewsRx.net) -- A therapeutic LMP1 polyepitope vaccine has been developed for Epstein-Barr virus (EBV)-associated Hodgkin's disease and nasopharyngeal carcinoma.
According to a study from Australia, "Development of an epitope-based vaccination strategy designed to enhance Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes (CTLs) is increasingly being considered as a preferred approach for the treatment of EBV-associated relapsed Hodgkin disease (HD) and nasopharyngeal carcinoma (NPC). EBV-encoded latent membrane proteins, LMP1 and LMP2, are the only target antigens available for therapeutic augmentation of CTL responses in patients with HD and NPC. Here, we describe preclinical studies using a recombinant poxvirus vaccine that encodes a polyepitope protein comprising 6 HLA A2-restricted epitopes derived from LMP1."
"Human cells infected with this recombinant polyepitope construct were efficiently recognized by LM1-specific CTL lines from HLAA2 healthy individuals," reported Jaikumar Duraiswamy and collaborators at the University of Queensland and Australian National University. "Furthermore, immunization of HLrA A2/K-b mice with this polyepitope vaccine consistently generated strong LMP1-specific CTL responses to five of the six epitopes, ...
Source: HighBeam Research, Therapeutic vaccine effective against EBV-associated cancers.